0000899243-22-034087.txt : 20221024 0000899243-22-034087.hdr.sgml : 20221024 20221024191007 ACCESSION NUMBER: 0000899243-22-034087 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221020 FILED AS OF DATE: 20221024 DATE AS OF CHANGE: 20221024 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Herron Jennifer Lyn CENTRAL INDEX KEY: 0001675774 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35420 FILM NUMBER: 221326908 MAIL ADDRESS: STREET 1: C/O GENOCEA BIOSCIENCES, INC. STREET 2: 100 ACORN PARK DRIVE 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ChemoCentryx, Inc. CENTRAL INDEX KEY: 0001340652 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943254365 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 835 INDUSTRIAL ROAD STREET 2: SUITE 600 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-210-2900 MAIL ADDRESS: STREET 1: 835 INDUSTRIAL ROAD STREET 2: SUITE 600 CITY: SAN CARLOS STATE: CA ZIP: 94070 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-10-20 1 0001340652 ChemoCentryx, Inc. CCXI 0001675774 Herron Jennifer Lyn C/O CHEMOCENTRYX, INC. 835 INDUSTRIAL ROAD, SUITE 600 SAN CARLOS CA 94070 1 0 0 0 Common Stock 2022-10-20 4 D 0 17237 D 0 D Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares. /s/ Susan M. Kanaya, as Attorney-in-Fact 2022-10-20